These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 34557493)
1. Hydrogen Sulfide Is a Novel Protector of the Retinal Glycocalyx and Endothelial Permeability Barrier. Allen CL; Wolanska K; Malhi NK; Benest AV; Wood ME; Amoaku W; Torregrossa R; Whiteman M; Bates DO; Whatmore JL Front Cell Dev Biol; 2021; 9():724905. PubMed ID: 34557493 [TBL] [Abstract][Full Text] [Related]
2. Endomucin restores depleted endothelial glycocalyx in the retinas of streptozotocin-induced diabetic rats. Niu T; Zhao M; Jiang Y; Xing X; Shi X; Cheng L; Jin H; Liu K FASEB J; 2019 Dec; 33(12):13346-13357. PubMed ID: 31545913 [TBL] [Abstract][Full Text] [Related]
3. Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes. Gamez M; Elhegni HE; Fawaz S; Ho KH; Campbell NW; Copland DA; Onions KL; Butler MJ; Wasson EJ; Crompton M; Ramnath RD; Qiu Y; Yamaguchi Y; Arkill KP; Bates DO; Turnbull JE; Zubkova OV; Welsh GI; Atan D; Satchell SC; Foster RR Cardiovasc Diabetol; 2024 Feb; 23(1):50. PubMed ID: 38302978 [TBL] [Abstract][Full Text] [Related]
4. Knockdown of fibrillin-1 suppresses retina-blood barrier dysfunction by inhibiting vascular endothelial apoptosis under diabetic conditions. Zhang Y; Liu XJ; Zhai XR; Yao Y; Shao B; Zhen YH; Zhang X; Xiao Z; Wang LF; Zhang ML; Chen ZM Int J Ophthalmol; 2024; 17(8):1403-1410. PubMed ID: 39156790 [TBL] [Abstract][Full Text] [Related]
5. The novel mitochondria-targeted hydrogen sulfide (H Gerő D; Torregrossa R; Perry A; Waters A; Le-Trionnaire S; Whatmore JL; Wood M; Whiteman M Pharmacol Res; 2016 Nov; 113(Pt A):186-198. PubMed ID: 27565382 [TBL] [Abstract][Full Text] [Related]
6. Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats. Si YF; Wang J; Guan J; Zhou L; Sheng Y; Zhao J Br J Pharmacol; 2013 Jun; 169(3):619-31. PubMed ID: 23488985 [TBL] [Abstract][Full Text] [Related]
7. Hydrogen Sulfide: A Potential Therapeutic Target in the Development of Diabetic Retinopathy. Mohammad G; Radhakrishnan R; Kowluru RA Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):35. PubMed ID: 33372981 [TBL] [Abstract][Full Text] [Related]
8. Hydrogen sulfide serves as a biomarker in the anterior segment of patients with diabetic retinopathy. Han Y; Zhang X; Zhou Z; Yu M; Wang Q; Yao J; Han Y Int Ophthalmol; 2020 Apr; 40(4):891-899. PubMed ID: 31894458 [TBL] [Abstract][Full Text] [Related]
9. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes. Klaassen I; Hughes JM; Vogels IM; Schalkwijk CG; Van Noorden CJ; Schlingemann RO Exp Eye Res; 2009 Jun; 89(1):4-15. PubMed ID: 19284967 [TBL] [Abstract][Full Text] [Related]
10. Decreased lysyl oxidase level protects against development of retinal vascular lesions in diabetic retinopathy. Kim D; Mecham RP; Nguyen NH; Roy S Exp Eye Res; 2019 Jul; 184():221-226. PubMed ID: 31022398 [TBL] [Abstract][Full Text] [Related]
11. Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy. Xie H; Zhang C; Liu D; Yang Q; Tang L; Wang T; Tian H; Lu L; Xu JY; Gao F; Wang J; Jin C; Li W; Xu G; Xu GT; Zhang J Diabetologia; 2021 Jan; 64(1):211-225. PubMed ID: 33104828 [TBL] [Abstract][Full Text] [Related]
13. Aflibercept ameliorates retinal pericyte loss and restores perfusion in streptozotocin-induced diabetic mice. Seo EJ; Choi JA; Koh JY; Yoon YH BMJ Open Diabetes Res Care; 2020 Oct; 8(1):. PubMed ID: 33077473 [TBL] [Abstract][Full Text] [Related]
14. AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. Szczesny B; Módis K; Yanagi K; Coletta C; Le Trionnaire S; Perry A; Wood ME; Whiteman M; Szabo C Nitric Oxide; 2014 Sep; 41():120-30. PubMed ID: 24755204 [TBL] [Abstract][Full Text] [Related]
15. Homocysteine and mitochondrial quality control in diabetic retinopathy. Malaviya P; Kowluru RA Eye Vis (Lond); 2024 Jan; 11(1):5. PubMed ID: 38229140 [TBL] [Abstract][Full Text] [Related]
17. Hydrogen sulfide attenuates myocardial fibrosis in diabetic rats through the JAK/STAT signaling pathway. Liu M; Li Y; Liang B; Li Z; Jiang Z; Chu C; Yang J Int J Mol Med; 2018 Apr; 41(4):1867-1876. PubMed ID: 29393353 [TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein 2: a potential new player in the pathogenesis of diabetic retinopathy. Hussein KA; Choksi K; Akeel S; Ahmad S; Megyerdi S; El-Sherbiny M; Nawaz M; Abu El-Asrar A; Al-Shabrawey M Exp Eye Res; 2014 Aug; 125():79-88. PubMed ID: 24910902 [TBL] [Abstract][Full Text] [Related]
19. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Broekhuizen LN; Lemkes BA; Mooij HL; Meuwese MC; Verberne H; Holleman F; Schlingemann RO; Nieuwdorp M; Stroes ES; Vink H Diabetologia; 2010 Dec; 53(12):2646-55. PubMed ID: 20865240 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models. Ting KK; Zhao Y; Shen W; Coleman P; Yam M; Chan-Ling T; Li J; Moller T; Gillies M; Vadas MA; Gamble JR Diabetologia; 2019 Feb; 62(2):322-334. PubMed ID: 30443753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]